Cytosorbents Corp. (CTSO) intrinsic value & 10-year financials
Cytosorbents Corp. (CTSO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 18.2% a year to $37.1M, with an average return on invested capital of -68.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.11
- Market cap
- $255.8M
- Revenue (FY2025)
- $37.1M
- Revenue growth (10-yr CAGR)
- 18.2%
- ROIC (10-yr avg)
- -68.0%
- Free cash flow (FY2025)
- -$12.5M
CTSO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $37.1M | -$8.2M | -$0.13 | -$12.5M | -39.8% | -45.0% |
| FY2024 | $35.6M | -$20.7M | -$0.38 | -$14.7M | -47.2% | -50.6% |
| FY2023 | $36.3M | -$28.5M | -$0.64 | -$22.2M | -85.9% | -103.8% |
| FY2022 | $34.7M | -$32.8M | -$0.75 | -$34.3M | -90.9% | -110.8% |
| FY2021 | $43.2M | -$24.6M | -$0.57 | -$17.6M | -52.7% | -137.7% |
| FY2020 | $41.0M | -$7.8M | -$0.20 | -$6.3M | -25.3% | -118.9% |
| FY2019 | $24.9M | -$19.3M | -$0.60 | -$17.5M | -76.0% | -288.3% |
| FY2018 | $20.3M | -$17.2M | — | -$11.5M | -77.0% | -353.5% |
| FY2017 | $13.4M | -$8.5M | — | -$7.5M | -73.6% | -857.6% |
| FY2016 | $8.2M | -$11.9M | — | -$6.9M | -140.0% | 1386.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cytosorbents Corp is a consistent compounder, expanding top-line revenue at 18.2% annually over the past decade.
Cytosorbents Corp has historically struggled to out-earn its cost of capital, averaging just -56.8% ROIC.
Over the decade, Cytosorbents Corp shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cytosorbents Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.32 per share.